Medoverine

Mebeverine Hydrochloride, the active ingredient in Medoverine, is an antispasmodic presented as an oral formulation for oral use. It is employed to relieve gastrointestinal smooth‑muscle spasms associated with irritable bowel syndrome and related functional bowel disorders in adult patients.

GNH USA supplies Medoverine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains, competitive pricing, and responsive technical support throughout the procurement process.

Mebeverine Hydrochloride is used to manage functional gastrointestinal disorders by relaxing smooth muscle.

- Irritable bowel syndrome: reduces abdominal cramping and improves bowel habit regularity. - Functional bowel disorders: alleviates spasmodic pain and discomfort associated with altered motility. - Colicky abdominal pain: diminishes intensity and frequency of painful colic episodes.

Mebeverine Hydrochloride may cause adverse reactions in some patients.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Nausea: mild stomach upset after oral intake. - Headache: transient cranial pain. - Dizziness: sensation of light‑headedness. - Abdominal discomfort: mild bloating or cramping. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling. - Severe skin eruption: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Angioedema: swelling of face, lips, or tongue. - Cardiac arrhythmia: irregular heartbeat in susceptible individuals. - Hepatotoxicity: abnormal liver function tests. - Anaphylaxis: life‑threatening systemic allergic response.

Before prescribing Medoverine, clinicians should consider several safety aspects.

- Assess renal function: adjust use in severe renal impairment. - Monitor hepatic function: use cautiously in patients with liver disease. - Check for hypersensitivity: avoid in individuals with known allergy to mebeverine. - Review concomitant antispasmodics: risk of additive smooth‑muscle relaxation. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original pack, protect from moisture and light.

Mebeverine may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors: may increase mebeverine plasma concentrations. - Other antispasmodics: additive smooth‑muscle relaxation can lead to excessive hypotonia. - QT‑prolonging drugs: combined use may raise the risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance dry‑mouth effects. - Tricyclic antidepressants: increased anticholinergic burden. - Antihistamines: potential for heightened sedation or dizziness.